Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Inventors

Cai, Xiong • Zhai, Haixiao • Lai, Chengjung • Qian, Changgeng • Bao, Rudi

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10543197-B2

Patent

Publication Date

2020-01-28

Expiration Date


Abstract

The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Core Innovation

The patent describes Compound (I) and pharmaceutically acceptable salts thereof, including Compound 1, as PI3K/HDAC dual-target small-molecule inhibitors comprising a zinc-binding moiety defined by Formula I. The disclosure presents the compounds as a dual-target approach to enable PI3K/HDAC inhibition in a single agent and as a treatment for cancer.

The invention relates to use of Compound (I) or a pharmaceutically acceptable salt thereof in combination with radiation for treating cancer. The treated cancer category includes oral cancer, laryngeal cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, bladder cancer, renal cancer, uterine cancer, ovarian cancer, testicular cancer, small-cell lung cancer, nonsmall-cell lung cancer, breast cancer, pancreatic cancer, melanoma, stomach cancer, medulloblastoma, glioblastoma, meningioma, and liver cancer.

The document further specifies internal radiation, external radiation, X-ray, gamma-ray, or particle radiation, and an oral administration route for Compound (I) or its salt. The examples describe biological activity consistent with inhibition of PI3K isoforms and HDAC activity, antiproliferative activity, in vivo pharmacokinetics and tumor efficacy with pathway modulation, oral bioavailability, tumor uptake/pharmacodynamic activity in mouse xenograft models, and potential synergy versus separate PI3K and HDAC inhibitors.

Claims Coverage

The independent claim coverage centers on one core therapeutic feature: administering Compound (I) or a pharmaceutically acceptable salt thereof and treating the subject with radiation to treat a listed cancer. Dependent refinements further specify radiation delivery, radiation type, cancer scope, and oral administration, giving six inventive features in total.

Treating a listed cancer with Compound (I) and radiation

A method of treating a cancer selected from oral cancer, laryngeal cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, bladder cancer, renal cancer, uterine cancer, ovarian cancer, testicular cancer, small-cell lung cancer, nonsmall-cell lung cancer, breast cancer, pancreatic cancer, melanoma, stomach cancer, medulloblastoma, glioblastoma, meningioma, or liver cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, and treating the subject with radiation.

Radiation administered internally

The method further provides that the radiation is administered internally.

Radiation administered externally

The method further specifies administering the radiation externally.

X-ray, gamma-ray, or particle radiation

The method is carried out using X-ray, gamma-ray, or particle radiation.

Solid tumor cancer

The method is applied to cancer that is a solid tumor.

Oral administration of Compound (I)

The method further includes orally administering Compound (I) or a salt thereof.

The claim coverage is directed to combination therapy using Compound (I) or its pharmaceutically acceptable salt with radiation for a broad list of cancers, with dependent limitations on internal or external radiation, X-ray, gamma-ray, or particle radiation, solid tumors, and oral administration.

Stated Advantages

Potent PI3K/HDAC inhibition.

Antiproliferative activity.

Oral bioavailability.

Tumor uptake/pharmacodynamic activity in mouse xenograft models.

Antitumor activity.

Safety described via an Ames test (genotoxicity safety).

Potential synergy versus separate PI3K and HDAC inhibitors.

Documented Applications

Treatment of cancer selected from oral cancer, laryngeal cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, bladder cancer, renal cancer, uterine cancer, ovarian cancer, testicular cancer, small-cell lung cancer, nonsmall-cell lung cancer, breast cancer, pancreatic cancer, melanoma, stomach cancer, medulloblastoma, glioblastoma, meningioma, or liver cancer, combined with radiation therapy.

Radiation-therapy contexts including internal and external radiation administration and the use of X-ray, gamma-ray, or particle radiation.

Therapeutic use in solid tumors.

Therapeutic use with oral administration of Compound (I) or a salt thereof.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.